Pulmonary toxicity associated with fludarabine monophosphate
โ Scribed by Paul G. Hurst; Michael P. Habib; Harinder Garewal; Marlene Bluestein; Maria Paquin; Bernard R. Greenberg
- Publisher
- Springer US
- Year
- 1987
- Tongue
- English
- Weight
- 789 KB
- Volume
- 5
- Category
- Article
- ISSN
- 0167-6997
No coin nor oath required. For personal study only.
โฆ Synopsis
Fludarabine monophosphate (FAMP), the 2-fluoro, 5'phosphate derivative of 9-/3-D-arabinofuranosyl adenine (ara-A), is a purine nucleoside antimetabolite presently undergoing clinical testing for the treatment of a variety of malignancies including lymphoproliferative disorders and acute leukemia. We report a case of diffuse interstitial pneumonitis during treatment of chronic lymphocytic leukemia with FAMP. This resolved quickly with high dose steroids, recurred with steroid withdrawal, and abated with further steroid therapy. To our knowledge, this is the first reported case of fludarabine monophosphate associated pulmonary toxicity.
๐ SIMILAR VOLUMES
A patient receiving mitomycin and vindesine chemotherapy for lung cancer developed abrupt onset of shortness of breath following vindesine administration. Pulmonary function tests both before and after rechallenging him with vindesine showed an acute obstructive pattern, which resolved with bronchod
Several adverse reactions are seen with gold therapy in rheumatoid arthritis (RA). Approximately 80% of such reactions are inconsequential, consisting of pruritis, rash, stomatitis, eosinophilia, and mild proteinuria (1,2). Nitritoid reactions are also frequent with the thiomalate preparation and us